Low Skeletal Muscle Index Predicts Neoadjuvant Immunochemotherapy Tolerance and Survival in Oesophageal Squamous Cell Carcinoma.

Authors

Yizhou Huang, Maohui Chen, Zhenyuan Yang, Bingqiang Cai, Yongcong Zhang, Hongjin Wang, Shuliang Zhang, Taidui Zeng, Chun Chen, Bin Zheng

Published in

Journal of cachexia, sarcopenia and muscle. Volume 17. Issue 5. Pages e70392.

Abstract

Low skeletal muscle index (SMI) may identify host vulnerability in patients receiving intensive cancer therapy. However, its association with treatment tolerance and outcomes during neoadjuvant immunochemotherapy (nICT) for oesophageal squamous cell carcinoma (OSCC) remains unclear.
This multicentre retrospective cohort included 461 patients with locally advanced OSCC who initiated nICT between 2020 and 2023; 404 underwent oesophagectomy. Pretreatment SMI at the third lumbar vertebra was measured by two blinded radiologists. Low SMI was defined using sex-specific outcome-derived cutoffs, with sensitivity analyses using published thresholds. Neoadjuvant treatment tolerance grade (NAT-TG) was used as a composite measure of treatment tolerance and feasibility, integrating treatment modification and failure to undergo curative surgery.
Among 461 patients (mean age, 61.2 ± 7.3 years; 21.3% female), low SMI was present in 121 (26.2%) and was independently associated with an unfavourable NAT-TG composite (NAT-TG2-3 vs. NAT-TG1; adjusted OR, 2.48; 95% CI, 1.62-3.82; p < 0.001). The association persisted after excluding six progression-related surgical omissions (adjusted OR, 2.51; 95% CI, 1.59-3.95; p < 0.001). The overall distribution of treatment-related adverse event severity differed between groups (p = 0.012), with grade ≥ 3 events occurring in 36.4% of patients with low SMI and 22.9% of those without low SMI. In the surgical population, low SMI was independently associated with severe postoperative complications (adjusted OR, 2.92; 95% CI, 1.51-5.63; p = 0.001). During a median follow-up of 43 months, 165 deaths occurred. The 1-year mortality rate in the intention-to-treat population was 8.5% (95% CI, 5.9%-11.0%). In the primary intention-to-treat model, low SMI was associated with poorer overall survival (adjusted HR, 2.36; 95% CI, 1.67-3.33; p < 0.001). Associations were also observed for surgical overall survival (adjusted HR, 1.91; 95% CI, 1.31-2.80) and disease-free survival (adjusted HR, 1.57; 95% CI, 1.11-2.22). Results were generally consistent when published SMI thresholds were applied.
Pretreatment low SMI was associated with less favourable nICT tolerance and feasibility, a higher incidence of severe postoperative complications and poorer survival. CT-derived skeletal muscle assessment may complement baseline risk stratification, while intervention strategies require prospective validation.

PMID:
42817217
Bibliographic data and abstract were imported from PubMed on 01 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.